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2 
Abstract 27 
Background Non-traumatic out of hospital cardiac arrest (OHCA) is the leading cause of death 28 
worldwide, mainly due to acute coronary syndromes. Urgent coronary angiography with view to 29 
revascularisation is recommended in patients with suspected acute coronary syndrome. Diagnosis 30 
and management of patients with inconclusive coronary angiogram (unobstructed coronaries or 31 
unidentified culprit lesion) is challenging. We sought to assess the role of Cardiovascular Magnetic 32 
Resonance (CMR) in the diagnosis and management of OHCA survivors with an inconclusive 33 
coronary angiogram. 34 
Methods and Results This is a retrospective multicentre CMR registry analysis of OHCA 35 
survivors with an inconclusive angiogram. Clinical, ECG and multi-modality imaging data were 36 
analysed. Clinical impact of CMR was defined as a change in diagnosis or management. Out of 174 37 
OHCA survivors referred for CMR, 110 patients (63%, 84 male, median age 58) had an 38 
inconclusive angiogram. CMR identified a pathologic substrate in 76/110 patients (69%): ischemic 39 
heart disease was found in 45 (41%) and non-ischemic heart disease in 31 (28%). A structurally 40 
normal heart was found in 25 patients (23%) and non-specific findings in 9 (8%). As compared to 41 
trans-thoracic echocardiogram, CMR proved to be superior in identifying a pathologic substrate 42 
(69% vs 54%, p=0.018). The CMR study carried a clinical impact in 70% of patients, determining a 43 
change in diagnosis in 25%, in management in 29% and a change in both in 16%.  44 
Conclusions CMR showed a promising role in the diagnostic work-up of OHCA survivors with 45 
inconclusive angiogram and its wider use should be considered.  46 
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3 
Introduction 53 
 54 
Non-traumatic out of hospital cardiac arrest (OHCA) is the leading cause of death worldwide (1-3) 55 
with an estimated incidence of 0.5/1000 person year (4-8).  Acute coronary syndromes (ACS) 56 
account for more than 2/3 of cases (9-12). According to AHA guidelines, urgent angiography with 57 
view to primary percutaneous coronary intervention is a class IB recommendation in patients with 58 
resuscitated cardiac arrest whose electrocardiogram (ECG) shows ST elevation (STE) myocardial 59 
infarction (MI) (13). Given the high incidence of underlying coronary artery disease (CAD) in this 60 
group of patients, European guidelines extended the recommendation to incorporate patients 61 
without diagnostic STE, but with high suspicion of on-going infarction (class IIaB) (14). However 62 
non-ischemic cardiomyopathy accounts for up to 15% of OHCA (15-19) and a structurally normal 63 
heart can be found in up to 10-20% of cases (20-23). While evidence of culprit lesion on angiogram 64 
supports acute ischemia as the cause of OHCA, diagnosis and clinical management of OHCA 65 
survivors with inconclusive coronary angiogram (either non-identifiable culprit lesion or 66 
unobstructed coronary arteries) is challenging. Cardiovascular magnetic resonance (CMR) is a non-67 
invasive imaging technique providing accurate diagnosis based on its superior spatial resolution and 68 
unique non-invasive tissue characterization. 69 
We sought to assess the additional role and clinical impact of CMR in the diagnosis and 70 
management of OHCA survivors with an inconclusive coronary angiogram.  71 
 72 
Materials and Methods 73 
The CMR registries from two tertiary Cardiac centres (Bristol, South West of England and Padua, 74 
Veneto Region, Italy) were analysed to identify OHCA survivors who underwent urgent coronary 75 
angiogram followed by CMR (October 2009-November 2015). The study focused on the analysis of 76 
patients with an “inconclusive angiogram”, defined as evidence of stable obstructive CAD (SCAD) 77 
with no culprit lesion or unobstructed coronaries (normal coronaries/non-obstructive CAD). Culprit 78 
4 
lesion was defined as obstructive (≥70%) CAD with TIMI 0/1 flow with abrupt closure, or TIMI 79 
2/3 flow with features suggestive of thrombus/ulcerated plaques, ST segment- T wave changes in 80 
the corresponding ECG location, and evidence of matching regional wall motion abnormality on 81 
left ventriculogram or echocardiogram (24).  82 
 83 
CMR 84 
CMR was performed on a 1.5T scanner (Avanto, Siemens Healthcare, Germany) with a protocol 85 
including long and short axis cine sequences and post-contrast imaging, performed ten minutes after 86 
intravenous administration of 0.1 mmol/Kg of Gadobutrol (Gadovist 1.0 mmol/ml, Bayer-Schering, 87 
Berlin, Germany) in identical planes to cine images. Additional sequences for the assessment of 88 
myocardial oedema (T2-short tau inversion recovery, T2-STIR) or myocardial ischemia (stress 89 
perfusion with 140 to 210 ug/Kg/min adenosine) were performed when indicated, based on clinical 90 
and angiographic findings. Ventricular function was assessed with dedicated software (Circle 91 
Cardiovascular Imaging, Calgary, Canada), by tracing endo- and epicardial borders on each short 92 
axis cine slice in end-diastole and end-systole. All volumes were indexed to body surface area. The 93 
localization, extent and distribution pattern of late gadolinium enhancement (LGE) were assessed 94 
by using short- and long-axis views and confirmed only if detectable in two orthogonal planes. The 95 
pattern of LGE distribution was defined as ischemic, subendocardial or transmural, if involving 96 
<50% or ≥50% of wall thickness, respectively, and as mid-wall/epicardial if patchy/spotty intra-97 
mural or sub-epicardial enhancement was detected. The presence of LGE at the right ventricle/left 98 
ventricle insertion points, in the absence of other distribution patterns, was defined as non-specific 99 
findings, as its diagnostic and prognostic meaning is still unclear.  100 
All the analyses were carried out in accordance with the recommendation of the Society for 101 
Cardiovascular Magnetic Resonance (25).  The study was reviewed by the local Institutional 102 
Research and Innovation Department and in view of the retrospective design, formal ethical 103 
approval was waived off. All patients gave written informed consent.  104 
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 105 
Clinical impact 106 
Clinical, ECG and echocardiographic data were collected and independently analysed by two 107 
clinicians blinded to CMR findings. A diagnosis was made based on clinical and imaging data 108 
available prior to CMR. According to previously used definitions (26), “clinical impact” of CMR 109 
was defined as change in diagnosis, compared to the composite pre-CMR diagnosis, or change in 110 
management. A change in management was defined as CMR findings either leading to change in 111 
medication, to an invasive procedure (i.e. repeat angiogram, myocardial revascularization, ICD 112 
implantation) or to the avoidance of such invasive procedures. Patients with a change both in 113 
diagnosis and management were only counted once. 114 
 115 
Statistical Analysis 116 
Continuous and categorical variables are expressed as mean±SD or median (IQR), and n (%), 117 
respectively. Categorical variables were compared by using the chi-square or Fisher exact test, as 118 
appropriate. Continuous data were compared by using the 2-tailed unpaired t test (for normally 119 
distributed data sets) or by using the Mann-Whitney U test. Inter-rater agreement for categorical 120 
variables was assessed by Cohen’s kappa coefficient. A p-value of <0.05 was considered 121 
statistically significant. Data were analysed with SPSS® version 23 (IBM®).  122 
 123 
Results 124 
Clinical characteristics 125 
Out of 174 consecutive OHCA survivors referred to CMR after coronary angiogram (performed on 126 
same day of admission, IQR 0-2 days), 110 patients (63%, 84 male, age 58 years, IQR 46-68) had 127 
an inconclusive angiogram and were enrolled in the study: 37 patients (34%) had evidence of 128 
SCAD with no culprit lesion and 73 patients (66%) showed unobstructed coronaries. The first 129 
registered rhythm was ventricular tachycardia (VT)/ventricular fibrillation (VF) in 104 patients 130 
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(95%) and pulseless electrical activity (PEA) in 6 patients (5%). The first ECG was available in 86 131 
patients (78%): non-ST elevation (non-STE) was reported in 68 patients (79%), STE in 18 (21%). 132 
SCAD patients with no culprit lesion were more frequently men (p=0.006) and significantly older 133 
compared to patients with unobstructed coronaries (p<0.001); risk factors were similar, except for 134 
hypertension (p=0.001) and known CAD (p <0.001), which were more frequent among SCAD 135 
patients with no culprit lesion. STE was more common among SCAD patients with no culprit 136 
(p=0.002). Patients’ characteristics are listed in Table 1. 137 
 138 
CMR findings 139 
Among patients with inconclusive angiogram, CMR was performed within 2 weeks from the index 140 
event (median 1.4 weeks, IQR 0.9-2.4, no difference between centres, p=0.588). Time to CMR was 141 
significantly shorter among patients with inconclusive angiogram, as compared to patients found to 142 
have an acute coronary event on angiogram (p=0.001). Median left ventricular ejection fraction 143 
(LVEF) was 57% (IQR 44-64), median indexed left ventricular end-diastolic volume (LViEDV) 144 
and end-systolic volume (LViESV) was 87 ml/m2 (IQR 73-110) and 38 ml/m2 (IQR 27-56), 145 
respectively. LVEF was significantly higher among patients with unobstructed coronaries (p 146 
<0.001). Wall motion abnormality was reported in 55 patients (50%), with regional  or diffuse 147 
pattern in 38 (35%) and 17 patients (15%), respectively (Table 2). 148 
On post-contrast sequences LGE was found in 72/110 patients (65%), and it was significantly more 149 
common among SCAD patients with no culprit lesion (33/37 vs 39/73, p <0.001). Analysis of LGE 150 
distribution pattern showed subendocardial LGE in 15 patients (14%), mid-wall/epicardial in 26 151 
patients (24%), and transmural LGE in 27 patients (25%). More than one distribution pattern was 152 
reported in 4 patients (3%). No LGE was found in 38 patients (34%). T2-STIR sequences for 153 
myocardial oedema were performed in 58 patients (53%), more frequently in patients with 154 
unobstructed coronaries (p=0.001); myocardial oedema was found in 18 patients (31%). Presence of 155 
myocardial oedema was not significantly associated with the timing of CMR; however, there was a 156 
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trend towards a higher prevalence of myocardial oedema among patients undergoing CMR within 157 
one week from index event (p=0.064).  There was no difference in prevalence of myocardial 158 
oedema between the two groups.  159 
Overall, CMR identified a pathologic substrate in 69% of the population: IHD was the final 160 
diagnosis in 45 patients (41%) and non-ischemic heart disease (NIHD) in 31 (28%). Non-specific 161 
findings were found in 9 patients (8%) and a structurally normal heart in 25 (23%)(Table 3). CMR 162 
findings between the two subgroups differed significantly (p<0.001)(Figure 1 and Supplementary 163 
File 1) 164 
 165 
Stable obstructive CAD with no culprit lesion 166 
Thirty-four patients (92%) were found to have IHD, a structurally normal heart (no myocardial 167 
oedema, late enhancement or inducible ischemia) was found in 3 (8%). On T2-STIR sequences, 168 
performed in 11 patients (30%), myocardial oedema was found in a single coronary artery territory 169 
in 5 (45%), helping to localise the culprit lesion. Stress perfusion CMR was performed in 15 170 
patients (41%): inducible ischemia was reported in 10 patients (67%) (single coronary artery 171 
territory in 7 patients and multi-vessel territory in 3), 90% of whom received percutaneous/surgical 172 
revascularization. A viability study was performed in the remaining 22 (59%) to guide treatment 173 
(revascularization/ optimization of medical therapy); CMR showed findings consistent with viable 174 
myocardium in 15 patients (68%), of which 12 (80%) underwent revascularization. 175 
 176 
Unobstructed coronaries 177 
IHD was diagnosed in 11 patients (15%) and NIHD in 31 (43%), with myocarditis (23%) and DCM 178 
(10%) being the most common, followed by congenital and acquired cardiomyopathies (Table 3). 179 
A structurally normal heart was found in 22 patients (30%) and non-specific findings in 9 180 
(12%)(Figure 2). On T2-STIR sequences, performed in 64% of patients, the presence of 181 
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myocardial oedema in 13 (28%) identified an acute, reversible, cause of OHCA in 3 IHD patients 182 
and in those diagnosed with myocarditis and TTC. LGE was found in 53%.  183 
 184 
Comparison between CMR and trans-thoracic echocardiogram 185 
A trans-thoracic echocardiogram (TTE) performed within 1 week from CMR was available in 92 186 
patients (84%). Median LVEF by TTE was lower compared to CMR (50% vs 57%, p <0.001). TTE 187 
identified a pathologic substrate in 50/92 patients (54% vs 69% by CMR, p=0.018): the final 188 
diagnosis was IHD in 26/92 patients (28%) and NIHD in 24/92 patients (26%). A structurally 189 
normal heart was found in 20/92 patients (22%) and non-specific findings (structural and functional 190 
abnormalities not attributable to a conclusive diagnosis) in 22 (24%). CMR and TTE provided the 191 
same diagnosis in 51/92 patients (55%)(Table 4). There was a moderate agreement between CMR 192 
and TTE with regards to IHD, which was confirmed on CMR in 22/26 patients (85%)(Cohen’s 193 
kappa 0.50), and to structurally normal heart, confirmed on CMR in 11/20 patients (55%)(Cohen’s 194 
kappa 0.43). There was a fair agreement with regards to NIHD, which was confirmed on CMR in 195 
15/24 patients (63%)(Cohen’s kappa 0.21); based on tissue characterization CMR identified 7 196 
patients with an ischemic distribution pattern of LGE. CMR provided a diagnosis in 14/22 (64%) 197 
patients with non-specific findings on TTE, identifying 6 patients with IHD and 8 patients with 198 
NIHD. The ability of CMR to be more definite regarding the underlying cardiac abnormalities was 199 
mainly based on LGE.  200 
 201 
Clinical impact of CMR 202 
CMR provided a clinical impact in 77/110 patients (70%), leading to change in diagnosis in 27 203 
patients (25%), in management in 32 (29%), and both in diagnosis and management in 18 patients 204 
(16%). An entirely new diagnosis was found in 25% of patients, most commonly structurally 205 
normal heart (11%) and NIHD (10%). CMR led to an invasive procedure in 32 (29%) patients, 206 
namely myocardial revascularization in 21 (19%) and ICD implantation in 11 (10%). Based on 207 
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CMR findings, an invasive procedure was avoided in 15 (14%) patients. CMR had greater clinical 208 
impact in SCAD patients with no culprit lesion (p=0.002), more frequently experiencing a change 209 
in management (86% vs. 25% unobstructed coronaries, p <0.001); a change in diagnosis occurred 210 
more frequently among patients with unobstructed coronaries (58% vs. 8% SCAD patients, p 211 
<0.001). 212 
 213 
Discussion 214 
The main findings of our study were that: 1) 2/3 of OHCA survivors referred to CMR have 215 
inconclusive findings on angiogram; 2) CMR identified a pathologic substrate in 69% of the 216 
population and a structurally normal heart in 23%; 3) CMR had a clinical impact in more than two 217 
thirds of patients. 218 
 219 
Acute coronary syndromes account for more than two thirds of OHCA (9-12) mainly secondary to 220 
acute coronary thrombosis (26) or ruptured plaque (27), as confirmed by autopsy series. 221 
International guidelines recommend urgent angiography in OHCA survivors with STE (13, 14) or 222 
whenever there is high suspicion of on-going infarction, irrespective of ECG (14). However, only a 223 
minority of cases (30-40%) shows angiographic and clinical evidence of ACS (27), a figure similar 224 
to that (37%) in our study. Causes other than acute ischemia are reported in up to 30% of cases (28). 225 
When acute ischemia is the obvious cause of OHCA, fewer patients are referred to CMR, mainly to 226 
assess the extent of myocardial scarring and the functional significance of bystander CAD. On the 227 
other hand, an inconclusive angiogram poses a diagnostic dilemma requiring further investigation, 228 
and to our knowledge this is the first study looking at the role and clinical impact of CMR in OHCA 229 
survivors with this angiographic finding. Identifying OHCA aetiology is often challenging in the 230 
acute setting, as clinical data are often lacking and ECG and echocardiographic interpretation might 231 
be affected by resuscitation manoeuvres or external defibrillation (27, 29). However, correct 232 
identification of the underlying cause, especially if reversible, plays a determinant role for 233 
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appropriate treatment strategy and long-term prognosis. CMR has a well-established diagnostic 234 
role, both in the ischemic and non-ischemic scenario, based on its superior tissue characterization 235 
properties. In our study, CMR could identify an underlying pathologic substrate in 69% of the 236 
population, as compared to 54% by TTE (p=0.018), and this was mainly due to LGE analysis. This 237 
superior diagnostic ability carried additional value and clinical impact over TEE in the management 238 
of these patients; for example, non-specific findings were more frequently reported by TTE (24% vs 239 
8%), but CMR was able to identify a pathologic substrate in two thirds of them. We found a high 240 
prevalence of LGE among OHCA survivors (65%), in keeping with that recently reported by Neilan 241 
(71%) in OHCA survivors referred to CMR because of an unclear diagnosis (after clinical and 242 
diagnostic assessment) (30). The aim of their study was to identify the role of LGE as an arrhythmic 243 
substrate and as a predictor of adverse cardiovascular events. They found that LGE presence and 244 
extent are the strongest predictors of adverse arrhythmic outcome, further confirming the 245 
relationship between myocardial damage and major arrhythmias, and strengthening the association 246 
between tissue characterization and arrhythmic risk, independent of the ejection fraction, as 247 
reported by many studies on cardiovascular outcome (31-35). White et al. (36) showed that CMR-248 
based imaging had a pick-up diagnostic rate of 74% in identifying the myocardial substrate of 249 
ventricular arrhythmias vs. 51% based on non-CMR imaging (i.e. diagnosis of MI missed in one 250 
third of patients on non-CMR imaging). In our study, CMR identified ischemic myocardial damage 251 
in 11 patients (15%) with unobstructed coronaries on angiogram; TTE diagnosed IHD in only one 252 
of them. Among 88 patients with no label of prior MI, Neilan (30) found ischemic LGE in 49, thus 253 
supporting the hypothesis that the presence of LGE in patients with unobstructed coronaries 254 
identifies a subgroup of patients at increased risk of arrhythmic events. Compared to Neilan, our 255 
study explored the comparative value of CMR vs TTE, as well as the clinical impact of CMR in this 256 
patients’ cohort.  257 
As already confirmed in different populations, such as in heart failure (26), we found that CMR 258 
changed both diagnosis and management in a considerable proportion of OHCA survivors (70%). 259 
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Of interest, CMR showed a clinical impact both in patients with unobstructed coronaries, mainly by 260 
providing a change in diagnosis, and in SCAD patients with no culprit lesion, mainly by a change in 261 
management. An entirely new diagnosis was identified in 25% of cases, mainly based on tissue 262 
characterization: a structurally normal heart was found in 11% of patients, based on the absence of 263 
LGE, and NIHD was diagnosed in 10%. Stress perfusion CMR has a well-established role not only 264 
in detecting CAD and guiding subsequent treatment strategy (37-39), but also in the identification 265 
of patients at increased risk of major adverse cardiovascular events (40, 41). Stress perfusion CMR, 266 
performed in nearly half of SCAD patients with no culprit lesion, found inducible ischemia in 67% 267 
of patients, guiding myocardial revascularization in nearly all of them. It is well-established that 268 
CMR has a role, over and above TTE, in re-classifying patients with regards to primary prevention 269 
ICD eligibility based on LVEF criteria (42), as it is the gold standard for LV function (43). The 270 
ability of CMR to detect reversible myocardial damage could play a role in guiding secondary 271 
prevention ICD implantation. In our patient population of OHCA survivors, CMR identified acute 272 
reversible myocardial injury (acute myocarditis and acute ischemia), thus avoiding secondary ICD 273 
implantation, as per guidelines, in 6% of patients.  274 
 275 
Limitations 276 
The main limitation of this study is the retrospective design. However, conducting a prospective 277 
trial in OHCA survivors might be difficult due to high mortality rate, variable downtime and 278 
consent. Sequences for myocardial oedema were available for analysis in half of the population, 279 
thus the clinical impact of oedema analysis might have been higher if performed in all patients. A 280 
structurally "normal" heart by TTE and CMR reflects the absence of gross ischemic or non-281 
ischemic underlying conditions, but it cannot exclude ultra-structural abnormalities. Although 282 
endomyocardial biopsy is the gold standard to assess myocardial abnormalities, it is an invasive 283 
technique, not widely performed clinically and not performed in our patients; therefore some more 284 
subtle histological and cellular abnormalities cannot be excluded. With all the above limitations, 285 
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this is a real world study that reflects clinical practice in most centres.  Our study only analysed the 286 
presence of focal fibrosis, although it is increasingly evident that the presence of diffuse fibrosis has 287 
a prognostic role, detecting patients at higher risk of fatal arrhythmias (44). The use of the most 288 
recent T1 mapping technique might help further understand the pathologic substrate in this group of 289 
patients. 290 
 291 
Conclusions 292 
Although ACS account for the majority of OHCA, 63% of the survivors in our cohort had an 293 
inconclusive angiogram. CMR proved to be superior to TEE in the identification of a pathologic 294 
substrate for the event in this cohort (69% vs 54%, p=0.018) and its findings had a clinical impact 295 
in 70% of patients, providing a significant change both in diagnosis and in management. CMR 296 
showed a promising role in the clinical and diagnostic work-up of OHCA survivors with 297 
inconclusive angiogram and its wider use should be considered. Further prospective studies are 298 
warranted to confirm these results in a larger population. 299 
 300 
 301 
 302 
 303 
 304 
 305 
 306 
 307 
 308 
 309 
 310 
 311 
13 
Disclosures 312 
Dr Bucciarelli-Ducci is Consultant for Circle Cardiovascular Imaging.  313 
There is no relationship to industry to declare.  314 
 315 
Fundings 316 
This work was supported by the Bristol NIHR Cardiovascular Biomedical Research Unit at the 317 
Bristol Heart Institute. The views expressed are those of the authors and not necessarily those of the 318 
National Health Service, National Institute for Health Research, or Department of Health. 319 
 320 
 321 
 322 
 323 
 324 
 325 
 326 
 327 
 328 
 329 
 330 
 331 
 332 
 333 
 334 
 335 
 336 
 337 
14 
References 338 
 339 
1.  Mozaffarian D, Benjamin EJ, Go AS, et al. AHA Statistical Update Heart Disease and Stroke 340 
Statistics — 2015 Update A Report From the American Heart Association. Circulation 341 
2015;131:e29–322.  342 
 343 
2.  De Vreede-Swagemakers J, Gorgels AP, Dubois-Arbouw WI, van Ree JWet al. Out-of-344 
hospital cardiac arrest in the 1990s: a population-based study in the Maatrich area on 345 
incidence, characteristics and survival. J Am Coll Cardiol 1997;30(6):1500–5.  346 
 347 
3.  Gorgels AP, Gijsbers C, de Vreede-Swagemakers J, Lousberg A, Wellens HJ. Out-of-348 
hospital cardiac arrest--the relevance of heart failure. The Maastricht Circulatory Arrest 349 
Registry. Eur Heart J 2003;24:1204–9.  350 
 351 
4.  Engdahl J, Holmberg M, Karlson BW, Luepker R, Herlitz J. The epidemiology of out-of-352 
hospital “sudden” cardiac arrest. Resuscitation 2002;52(3):235–45.  353 
 354 
5.  Berdowski J, Berg RA, Tijssen JG, Koster RW. Global incidences of out-of-hospital cardiac 355 
arrest and survival rates: Systematic review of 67 prospective studies. Resuscitation 356 
2010;81(11):1479-87. 357 
 358 
6.  McNally B, Robb R, Mehta M, et al. Out-of-hospital cardiac arrest surveillance --- Cardiac 359 
Arrest Registry to Enhance Survival (CARES). MMWR Surveill Summ Morb Mortal Wkly 360 
report Surveill Summ / CDC 2011;60(8):1–19.  361 
15 
 362 
7.  Wnent J, Masterson S, Gräsner JT, et al. EuReCa ONE – 27 Nations, ONE Europe, ONE 363 
Registry: a prospective observational analysis over one month in 27 resuscitation registries in 364 
Europe – the EuReCa ONE study protocol. Scand J Trauma Resusc Emerg Med 2015;23:3–365 
8.  366 
 367 
8.  Cone DC, Middleton PM. Are out-of-hospital cardiac arrest survival rates improving? 368 
Resuscitation 2015;91:A7-A8. http://dx.doi.org/10.1016/j.resuscitation.2015.03.011 369 
 370 
9.  Mehta D, Curwin J, Gomes JA, Fuster V. Sudden death in coronary artery disease: acute 371 
ischemia versus myocardial substrate. Circulation 1997;96(9):3215–23.  372 
 373 
10.  Myerburg RJ, Junttila MJ. Sudden cardiac death caused by coronary heart disease. 374 
Circulation 2012;125(8):1043–52.  375 
 376 
11.  Arsenos P, Gatzoulis K, Dilaveris P, et al. Arrhythmic Sudden Cardiac Death: substrate, 377 
mechanism and current risk stratification strategies for the post-myocardial infarction patient. 378 
Hell J Cardiol 2013;(54):301–15.  379 
 380 
12.  Zaman S, Kovoor P. Sudden cardiac death early after myocardial infarction. Pathogenesis, 381 
risk stratification, and primary prevention. Circulation 2014;129(23):2426–35.  382 
 383 
13.  O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA Guideline for the 384 
Management of ST-Elevation Myocardial Infarction: Executive Summary: A Report of the 385 
16 
American College of Cardiology Foundation/American Heart Association Task Force on 386 
Practice Guidelines. Circulation 2013;128(16):e240–327.  387 
 388 
14.  Steg S, James SK, Atar A, et al.  ESC Guidelines for the management of acute myocardial 389 
infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569–619.  390 
 391 
15.  Mazeika P. Aborted sudden cardiac death: a clinical perspective. Postgrad Med J. 392 
2001;77(908):363–70.  393 
 394 
16.  Stojanovska J, Garg A, Patel S, Melville DM, Kazerooni EA, Mueller GC. Congenital and 395 
Hereditary Causes of Sudden Cardiac Death in Young Adults : Diagnosis, Differential 396 
Diagnosis, and risk stratification. Radiographics 2013;33(7):1977–2001.  397 
 398 
17.  Koutalas E, Kanoupakis E, Vardas P. Sudden cardiac death in non-ischemic dilated 399 
cardiomyopathy: A critical appraisal of existing and potential risk stratification tools. Int J 400 
Cardiol 2013;167(2):335–41.  401 
 402 
18.  O’Mahony C, Elliott P, McKenna W. Sudden cardiac death in hypertrophic cardiomyopathy. 403 
Circ Arrhythmia Electrophysiol 2013;6(2):443–51.  404 
 405 
19.  Lubitz SA, Goldbarg SH, Mehta D. Sudden Cardiac Death in Infiltrative Cardiomyopathies: 406 
Sarcoidosis, Scleroderma, Amyloidosis, Hemachromatosis. Prog Cardiovasc Dis 407 
2008;51(1):58–73.  408 
 409 
17 
20.  Chugh SS. Sudden cardiac death with apparently normal heart: clinicla implication of 410 
progress in pathophysiology. Card Electrophysiol Rev 2001;(5):394–402.  411 
 412 
21.  Corrado D, Basso C, Thiene G. Sudden cardiac death in young people with apparently 413 
normal heart. Cardiovasc Res 2001;50(2):399–408.  414 
 415 
22.  Consensus statement of the Joint Steering Committees of the Unexplained Cardiac Arrest 416 
Registery of Europe and of the Idiopathic Ventricular Fibrillation Registry of the United 417 
States. Survivors of Out-of-Hospital Cardiac Arrest With Apparently Normal Heart: Need for 418 
Definition and Standardized Clinical Evaluation. Circulation 1997;95:265-272.   419 
 420 
23.  Semsarian C, Ingles J, Wilde AA. Sudden cardiac death in the young: the molecular autopsy 421 
and a practical approach to surviving relatives. Eur Heart J 2015;36(21):1290-6. 422 
 423 
24.  Noc M., Fajadet J, Lassen J.F., et al. Invasive coronary treatment strategiesfor out-of-hospital 424 
cardiac arrest: a consensus statement from the European Association for Percutaneous 425 
Cardiovascular Intervention (EAPCI)/Stent for Life (SFL) groups. Eurointervention 426 
2014;10:31-7.  427 
 428 
25.  Schulz-Menger J, Bluemke DA, Bremerich J, et al. Standardized image interpretation and 429 
post processing in cardiovascular magnetic resonance : Society for Cardiovascular Magnetic 430 
Resonance ( SCMR ) Board of Trustees Task Force on Standardized Post Processing. J 431 
Cardiovasc Magn Reson 2013;15(1):35.  432 
 433 
18 
26.  Abbasi SA, Ertel A, Shah RV, et al. Impact of cardiovascular magnetic resonance on 434 
management and clinical decision-making in heart failure patients. J Cardiovasc Magn Reson 435 
2013;15(1):89.  436 
 437 
27.  Anyfantakis ZA, Baron G, Aubry P, et al. Acute coronary angiographic findings in survivors 438 
of out-of-hospital cardiac arrest. Am Heart J 2009;157:312–8.  439 
 440 
28.  Chelly J, Mongardon N, Dumas F, et al. Benefit of an early and systematic imaging 441 
procedure after cardiac arrest: Insights from the PROCAT (Parisian Region Out of Hospital 442 
Cardiac Arrest) registry. Resuscitation 2012;83(12):1444-50. 443 
 444 
29.  Price S, Uddin S, Quinn T. Echocardiography in cardiac arrest. Curr Opin Crit Care 445 
2010;16(3):211–5.  446 
 447 
30.  Neilan TG, Farhad H, Mayrhofer T, et al. Late Gadolinium Enhancement Among Survivors 448 
of Sudden Cardiac Arrest. JACC Cardiovasc Imaging 2015;8($):414-23.  449 
 450 
31.  Aljaroudi WA, Flamm SD, Saliba W, Wilkoff BL, Kwon D. Role of CMR imaging in risk 451 
stratification for sudden cardiac death. JACC Cardiovasc Imaging 2013;6(3):392–406.  452 
 453 
32.  Dawson DK, Hawlisch K, Prescott G, et al. Prognostic role of CMR in patients presenting 454 
with ventricular arrhythmias. JACC Cardiovasc Imaging 2013;6(3):335–44.  455 
 456 
33.  Tamene A, Tholakanahalli VN, Chandrashekhar Y. Cardiac imaging in evaluating patients 457 
19 
prone to sudden death. Indian Heart J 2014;66(SUPPL. 1):S61–70.  458 
 459 
34.  Almehmadi F, Joncas SX, Nevis I, et al. Prevalence of myocardial fibrosis patterns in 460 
patients with systolic dysfunction: prognostic significance for the prediction of sudden 461 
cardiac arrest or appropriate implantable cardiac defibrillator therapy. Circ Cardiovasc 462 
Imaging 2014;7:593–600.   463 
 464 
35.  Scott PA, Rosengarten JA, Curzen NP, Morgan JM. Late gadolinium enhancement cardiac 465 
magnetic resonance imaging for the prediction of ventricular tachyarrhythmic events: A 466 
meta-analysis. Eur J Heart Fail 2013;15(9):1019–27.  467 
 468 
36.  White JA, Fine NM, Gula L, et al. Utility of cardiovascular magnetic resonance in 469 
identifying substrate for malignant ventricular arrhythmias. Circ Cardiovasc Imaging 470 
2012;5:12–20.  471 
 472 
37.  Schwitter J, Wacker CM, van Rossum AC, et al. MR-IMPACT: Comparison of perfusion-473 
cardiac magnetic resonance with single-photon emission computed tomography for the 474 
detection of coronary artery disease in a multicentre, multivendor, randomized trial. Eur 475 
Heart J 2008;29(4):480–9.  476 
 477 
38.  Schwitter J, Wacker CM, Wilke N, et al. Superior diagnostic performance of perfusion-478 
cardiovascular magnetic resonance versus SPECT to detect coronary artery disease: The 479 
secondary endpoints of the multicenter multivendor MR-IMPACT II (Magnetic Resonance 480 
Imaging for Myocardial Perfusion Assessm. J Cardiovasc Magn Reson 2012;14(1):61.  481 
 482 
20 
39.  Greenwood JP, Maredia N, Radjenovic A, et al. Clinical evaluation of magnetic resonance 483 
imaging in coronary heart disease: the CE-MARC study. Trials 2009;10:62.  484 
 485 
40.  Lipinski MJ, McVey CM., Berger JS, Kramer CM, Salerno M. Prognostic value of stress 486 
Cardiac Magnetic Resonance Imaging in patients with known or suspected coronary artery 487 
disease: a systematic review and meta-analysis. J Am Coll Cardiol 2013;62(9):826-838.  488 
 489 
41.  Pereira E, Bettencourt N, Ferreira N, et al. Incremental value of adenosine stress cardiac 490 
magnetic resonance in coronary artery disease detection. Int J Cardiol 2013;168(4):4160–7.  491 
 492 
42.  Joshi SB, Connelly KA, Jimenez-Juan L, et al. Potential clinical impact of cardiovascular 493 
magnetic resonance assessment of ejection fraction on eligibility for cardioverter defibrillator 494 
implantation. J Cardiovasc Magn Reson 2012;14:69.  495 
 496 
43.  Pennell DJ. Ventricular volume and mass by CMR. J Cardiovasc Magn Reson. 497 
2002;4(4):507–13.  498 
 499 
44. Wong TC, Piehler K, Meier CG, et al. Association between extracellular matrix expansion 500 
quantified by cardiovascular magnetic resonance and short-term mortality. Circulation 2012; 501 
126: 1206-16. 502 
 503 
 504 
 505 
 506 
21 
Figure Legends 507 
Figure 1. CMR findings in OHCA survivors with inconclusive angiogram  508 
Final CMR findings, according to coronary angiogram data, in OHCA survivors with inconclusive 509 
angiogram. Boxes in bold show the final CMR findings in the overall cohort of OHCA survivors 510 
with inconclusive angiogram. SCAD, stable coronary artery disease. 511 
 512 
Figure 2. CMR findings. 513 
Post-contrast 3 chamber long-axis view showing transmural myocardial infarction (A). Post-514 
contrast 3 chamber long-axis view of a patient with hypertrophic cardiomyopathy (HCM) and 515 
replacement fibrosis of the hypertrophied septum (B, arrow). Post-contrast 4 chamber long axis 516 
view of a patient with biventricular arrhythmogenic right ventricular cardiomyopathy (ARVC) (C). 517 
3 chamber long axis cine showing prolapse of the posterior mitral leaflet at end-systole (D). Post-518 
contrast short axis view showing epicardial enhancement of the basal lateral wall in a patient with 519 
healed myocarditis (E, arrow). Post-contrast short axis view showing non- specific late 520 
enhancement of the inferior insertion point (F, arrow).  521 
 522 
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Supplementary Material 533 
Supplementary File 1. CMR findings according to coronary angiogram results 534 
Top panel, no culprit lesion identified on angiogram: ischemic heart disease (IHD) was the most 535 
common diagnosis, although CMR identified a structurally normal heart in 8% of patients. Bottom 536 
panel, unobstructed coronary arteries: non-ischemic heart disease (NIHD) and structurally normal 537 
heart were the most common findings, but CMR identified an ischemic cardiomyopathy in 15% of 538 
patients.  539 
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